IRadimed's transition to the 3870 pump platform marks a pivotal inflection, with revenue growth stalling to 0.3% year-over-year in 2026Q2 and gross margin compressing to 74.1%, the lowest in the reported period. Despite this, the company maintains a fortress b...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 31, 2026 | $0.46+4.5% vs $0.44 | $20M+0.6% vs $20M |
Q2 2026 May 1, 2026 | $0.49+8.9% vs $0.45 | $22M+3.1% vs $21M |
Q1 2026 Feb 10, 2026 | $0.54+10.2% vs $0.49 | $23M+5.1% vs $22M |
Q4 2025 Nov 3, 2025 | $0.47-2.1% vs $0.48 | $21M-1.8% vs $22M |
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference.
iRadimed (NASDAQ: IRMD - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Insider and Institutional Ownership 92.3% of iRadimed shares are owned
On September 04, 2026, iRadimed Corp (IRMD) shares fell 3.8%, currently trading at $83.45. The stock has seen a notable decline, with a 52-week high of $107.90
Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider's stock after selling 15,062 shares during the period. Algert Global
Benchmark IRMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for IRadimed Corporation (IRMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $85.40 | $1.09B | 48.80 | 14.43% | 26.82% | 24.78% | 1.37% | |
| $99.96 | $6.51B | 29.31 | 0.5% | 17.69% | 23.27% | — | |
| $17.16 | $976.73M | -9.98 | 37.22% | -32.54% | -30.62% | — | |
| $15.11 | $624.53M | -17.17 | 9.46% | -11.48% | -21.01% | — | |
| $14.94 | $1.73B | -12.25 | 8.28% | -21.25% | -44% | — | |
| $64.29 | $29.04B | 14.13 | 4.84% | 7.86% | 14.91% | — |
IRadimed Corporation (IRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
IRadimed Corporation (IRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 31, 2026·SEC
Jun 24, 2026·SEC
May 1, 2026·SEC
Get notified when IRMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IRadimed Corporation (IRMD) stock FAQ — growth, dividends, profitability & financials explained
IRadimed Corporation (IRMD) reported $86.3M in revenue for fiscal year 2025. This represents a 1023% increase from $7.7M in 2012.
IRadimed Corporation (IRMD) grew revenue by 14.4% over the past year. This is steady growth.
Yes, IRadimed Corporation (IRMD) is profitable, generating $23.1M in net income for fiscal year 2025 (26.8% net margin).
Yes, IRadimed Corporation (IRMD) pays a dividend with a yield of 1.37%. This makes it attractive for income-focused investors.
IRadimed Corporation (IRMD) has a return on equity (ROE) of 24.8%. This is excellent, indicating efficient use of shareholder capital.
IRadimed Corporation (IRMD) generated $24.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
